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Along with other widely used organophosphate
insecticides, chlorpyrifos (CPF) is undergoing
increasing scrutiny because of its developmental
neurotoxicity (Barone et al. 2000; Landrigan
2001; Landrigan et al. 1999; May 2000;
Physicians for Social Responsibility 1995; Pope
1999; Rice and Barone 2000; Slotkin 1999. In
press). Although originally all organophos-
phates were thought to elicit neuro-
developmental damage through inhibition of
cholinesterase (Mileson et al. 1998; Pope
1999), it is now apparent that other mecha-
nisms play an important, perhaps predominat-
ing role, involving concentrations below the
threshold for the systemic toxicity associated
with cholinergic hyperstimulation (Barone
et al. 2000; Das and Barone 1999; Pope 1999;
Schuh et al. 2002; Slotkin 1999, In press). CPF
itself, as distinct from CPF oxon, the active
metabolite that inhibits cholinesterase, disrupts
the fundamental processes of brain develop-
ment, such as DNA synthesis (Dam et al.
1998; Whitney et al. 1995), expression and
function of macromolecular constituents and
transcription factors that control cell differenti-
ation (Crumpton et al. 2000; Garcia et al.
2001; Johnson et al. 1998; Schuh et al. 2002),
and expression and function of neurotransmit-
ters and their receptors that act as neuro-
trophins in the developing brain (Buznikov et
al. 2001; Dam et al. 1999a, 1999b; Howard
and Pope 2002; Huff et al. 2001; Liu et al.
2002; Yanai et al. 2002; Zhang et al. 2002).
Although these studies provide a reasonable
doubt as to the importance of cholinesterase
inhibition for developmental neurotoxicity of
CPF, they leave open the issue of which cellular
targets are the most critical, most sensitive, or
primary in eliciting long-term changes in ner-
vous system development. One pathway that
has received much attention is that mediated by
the intracellular second messenger cyclic AMP
(cAMP), which ubiquitously coordinates the
critical transition from cell replication to cell
differentiation (Bhat et al. 1983; Claycomb
1976; Guidotti 1972; Hultgårdh-Nilsson et al.
1994; Van Wijk et al. 1973). In brain develop-
ment, cAMP ultimately inﬂuences cell division,
differentiation, axonal outgrowth, neural plas-
ticity, and programmed cell death (Shaywitz
and Greenberg 1999; Stachowiak et al. 2003),
events known to be targeted by CPF (Barone et
al. 2000; Das and Barone 1999; Pope 1999;
Schuh et al. 2002; Slotkin 1999. In press).
Furthermore, neurotransmitter receptors that
control adenylyl cyclase (AC), the enzyme
responsible for cAMP production, and AC
itself have been found to be targets for CPF
(Auman et al. 2000; Huff and Abou-Donia
1995; Huff et al. 1994, 2001; Olivier et al.
2001; Schuh et al. 2002; Song et al. 1997;
Ward and Mundy 1996; Yanai et al. 2002;
Zhang et al. 2002). One of the most sensitive
effects involves changes in the transcription fac-
tors that are downstream targets for cAMP and
that are known to participate in the activation
of the genes necessary for cell differentiation
(Schuh et al. 2002).
These findings thus raise the possibility
that actions on the AC pathway are among
the critical targets of CPF in the developing
brain. In the present study we explore this
prospect with an in vivo exposure model,
using CPF regimens that bracket the thresh-
old for cholinesterase inhibition and resultant
maternal/fetal toxicity (Qiao et al. 2002,
2003). We concentrated on two phases of
development, an early stage involving forma-
tion of the neural tube, gestational days (GD)
9–12, and a later stage involving the transition
from replication to differentiation of major
neuronal cell populations (GD17–20). In
both periods, CPF elicits mitotic abnormali-
ties, apoptosis, and architectural anomalies in
the developing brain at exposures that are not
otherwise embryotoxic (Lassiter et al. 2002;
Roy et al. 1998; White et al. 2002). At lower
exposure levels, CPF-induced damage is not
immediately apparent, but synaptic and func-
tional abnormalities appear later, in adoles-
cence and adulthood (Levin et al. 2002; Qiao
et al. 2002, 2003). Thus, if the production of
cAMP is involved in the adverse effects of
CPF on brain development, effects on the AC
signaling pathway should be evident immedi-
ately upon exposure to these lower exposures,
preceding the delayed-onset anomalies.
The potential effects of CPF on AC were
assessed in several ways. First, we evaluated
basal enzymatic activity. Second, we deter-
mined the response to two AC stimulants,
forskolin and manganese (Mn2+). Because the
two stimulants act at different epitopes on the
AC molecule, the preference for one over the
other reflects shifts in molecular conforma-
tion, primarily inﬂuenced by the AC isoform
(Zeiders et al. 1999b). Third, we probed the
AC response to specific receptor-mediated
activation with isoproterenol, a β-adrenocep-
tor (βAR) agonist that links to AC by activat-
ing the stimulatory G-protein, Gs. This
receptor has defined neurotrophic roles in
brain cell development and is a postulated tar-
get for CPF (Auman et al. 2000; Dreyfus
1998; Garcia et al. 2001; Kasamatsu 1985;
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The developmental neurotoxicity of chlorpyrifos (CPF) involves mechanisms over and above
cholinesterase inhibition. In the present study, we evaluated the effects of gestational CPF exposure
on the adenylyl cyclase (AC) signaling cascade, which regulates the production of cyclic AMP, a
major controller of cell replication and differentiation. In addition to basal AC activity, we assessed
the AC response to direct enzymatic stimulants [forskolin, manganese (Mn2+)]; the response to iso-
proterenol, which activates signaling through β-adrenoceptors (βARs); and the concentration of
βAR binding sites. CPF administered to pregnant rats on gestational days (GD) 9–12 elicited little
or no change in any components of AC activity or βARs. However, shifting the treatment window
to GD17–20 produced regionally selective augmentation of AC activity. In the brainstem, the
response to forskolin or Mn2+ was markedly stimulated by doses at or below the threshold for
observable toxicity of CPF or for inhibition of fetal brain cholinesterase, whereas comparable
effects were seen in the forebrain only at higher doses. In addition, low doses of CPF reduced βAR
binding without impairing receptor-mediated stimulation of AC. These results indicate that signal
transduction through the AC cascade is a target for CPF during a discrete developmental period in
late gestation, an effect that is likely to contribute to the noncholinergic component of CPF’s
developmental neurotoxicity. Key words: adenylyl cyclase, β-adrenoceptor, brain development,
chlorpyrifos, organophosphate insecticides. Environ Health Perspect 111:1871–1876 (2003).
doi:10.1289/ehp.6468 available via http://dx.doi.org/ [Online 29 August 2003]
Research ArticleKulkarni et al. 2002; Kwon et al. 1996;
Morris et al. 1983; Popovik and Haynes 2000;
Schwartz and Nishiyama 1994; Slotkin et al.
1989; Song et al. 1997; Yanai et al. 2002).
Materials and Methods
Materials. Animals were purchased from Zivic
Laboratories (Pittsburgh, PA, USA). CPF was
purchased from Chem Service (West Chester,
PA, USA). [125I]Iodopindolol (speciﬁc activ-
ity, 2,200 Ci/mmol) was obtained from
Perkin-Elmer Life Sciences (Boston, MA,
USA), and cAMP radioimmunoassay kits were
purchased from Amersham Pharmacia Biotech
(Piscataway, NJ, USA). All other chemicals
were purchased from Sigma Chemical Corp.
(St. Louis, MO, USA).
Animal treatments. All experiments using
live animals were carried out in accordance with
the declaration of Helsinki and with the Guide
for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources
1996). Timed-pregnant Sprague–Dawley rats
were housed in breeding cages, with a 12-hr
light–dark cycle and with free access to food
and water. CPF was dissolved in dimethyl sul-
foxide to provide rapid and complete absorp-
tion (Whitney et al. 1995) and was injected
subcutaneously in a volume of 1 mL/kg body
weight. For exposure during neurulation, dams
were injected daily with CPF at 1 or 5 mg/kg
body weight on GD9–12. Dams were decapi-
tated, and fetal tissues were harvested without
distinction by sex on GD17 and GD21. For
later gestational exposure (GD17–20), dams
were given CPF daily at 1, 2, 5, 10, 20, or 40
mg/kg, and tissues were collected on GD21.
Control animals received DMSO injections on
the same schedules. For samples collected on
GD17, we analyzed the whole brain, whereas
in GD21 samples the forebrain was separated
from the rest of the brain by making a cut ros-
tral to the thalamus; because the cerebellum
represents an inappreciable proportion of brain
weight on GD21, the rest of the brain was
considered to represent primarily the brain-
stem. This dissection, which follows the nat-
ural planes of the fetal and neonatal rat brain,
includes the corpus striatum, hippocampal for-
mation, and neocortex within the area desig-
nated as “forebrain.” The region designated as
“brainstem” includes the midbrain, colliculi,
pons, and medulla oblongata (but not cervical
spinal cord), as well as the thalamus. All tissues
were frozen with liquid nitrogen and main-
tained at –45°C until assayed.
Membrane preparation. Tissues were
thawed and homogenized (Polytron,
Brinkmann Instruments, Westbury, NY,
USA) in 39 volumes of ice-cold buffer con-
taining 145 mM NaCl, 2 mM MgCl2, and
20 mM Tris (pH 7.5), and the homogenates
were sedimented at 40,000 × g for 15 min.
The pellets were washed twice by resuspension
(Polytron) in homogenization buffer, followed
by resedimentation, and were then dispersed
with a homogenizer (smooth glass ﬁtted with
Teflon pestle) in a buffer consisting of
250 mM sucrose, 2 mM MgCl2, and 50 mM
Tris (pH 7.5).
Assays. To evaluate βAR binding, aliquots
of membrane preparation were incubated
with [125I]iodopindolol (final concentration,
67 pM), in 145 mM NaCl, 2 mM MgCl2,
1 mM sodium ascorbate, and 20 mM Tris
(pH 7.5), for 20 min at room temperature in
a total volume of 250 µL. Incubations were
stopped by dilution with 3 mL of ice-cold
buffer, and the labeled membranes were
trapped by rapid vacuum filtration onto
Whatman GF/C filters, which were then
washed with additional buffer and counted by
liquid scintillation spectrometry. Nonspeciﬁc
binding was assessed by displacement with
100 µM isoproterenol. Iodopindolol binds to
both β1ARs and β2ARs equally, which is
important in light of the presence of both
subtypes in the developing brain and their
effective linkage to AC (Erdtsieck-Ernste et al.
1991; Pittman et al. 1980; Slotkin et al.
1994, 2001).
For assessment of AC activity, aliquots of
the same membrane preparation were incu-
bated for 10 min at 30°C with ﬁnal concen-
trations of 100 mM Tris-HCl (pH 7.4),
10 mM theophylline, 1 mM ATP, 2 mM
MgCl2, 1 mg/mL bovine serum albumin, and
a creatine phosphokinase-ATP–regenerating
system consisting of 10 mM sodium phospho-
reatine and 8 IU/mL phosphocreatine kinase,
with 10 µM guanosine triphosphate (GTP) in
a total volume of 250 µL. The enzymatic reac-
tion was stopped by placing the samples in a
90–100°C water bath for 5 min, followed by
sedimentation at 3,000 × g for 15 min, and
the supernatant solution was assayed for
cAMP using radioimmunoassay. Preliminary
experiments showed that the enzymatic reac-
tion was linear well beyond the assay period
and was linear with membrane protein con-
centration; concentrations of cofactors were
optimal, and in particular, higher concentra-
tions of GTP produced no further augmenta-
tion of activity. In addition to measuring
basal AC activity, we assessed the response to
βAR stimulation (100 µM isoproterenol), as
well as the response to the direct AC stimu-
lants forskolin (100 µM) and Mn2+ (10 mM).
These concentrations of each stimulant pro-
duce maximal responses, as assessed in previ-
ous studies (Auman et al. 2000, 2001; Zeiders
et al. 1997, 1999a).
Data analysis. Because the treatments
were given to the dams, only one fetus was
used from each dam, so the number of deter-
minations represents the number of dams.
The fetuses were derived from the same litters
as those used in two previous studies on cell
damage and cholinergic biomarkers; therefore
effects on cholinesterase activity, maternal
and fetal body weights, and other litter char-
acteristics have been published elsewhere
(Garcia et al. 2002; Qiao et al. 2002). 
Data are presented as mean ± SE. For con-
venience, some results are given as the percent
change from control values, but statistical eval-
uations were always conducted on the original
data. To establish treatment differences in
receptor binding or AC activity, a global analy-
sis of variance (ANOVA; data log transformed
whenever variance was heterogeneous) was ﬁrst
conducted across in vivo treatment groups, age,
brain region, and the five types of measure-
ments made on the membranes (βAR binding,
AC activity under four different conditions);
the AC measurements were considered to be
repeated measures because each membrane
preparation was used for the multiple types of
determinations. As justified by significant
interactions of treatment with the other vari-
ables, data were then subdivided to permit test-
ing of individual treatments and AC measures
that differed from control values; these were
conducted by lower-order ANOVAs followed,
where appropriate, by Fisher’s protected least
signiﬁcant difference to identify individual val-
ues for which the CPF groups differed from
the corresponding control. For all tests, we
assumed signiﬁcance for main treatment effects
at p < 0.05; however, for interactions at p <
0.1, we also examined whether lower-order
main effects were detectable after subdivision
of the interactive variables (Snedecor and
Cochran 1967).
For presentation, control values from
GD21 samples were combined across both
cohorts (controls used for CPF administra-
tion on GD9–12 and GD17–20). However,
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Table 1. Development of βAR binding and AC activities in controls.
GD17 whole brain GD21 forebrain GD21 brainstem
Measure (n = 6) (n = 17) (n = 18)
βAR binding (fmol/mg protein) 4.7 ± 0.3 8.0 ± 0.3 10.9 ± 0.5a
Basal AC (pmol/min/mg protein) 83 ± 5 92 ± 3 589 ± 28a
Isoproterenol-stimulated AC (pmol/min/mg protein) 91 ± 6 94 ± 4 636 ± 27a
Forskolin-stimulated AC (pmol/min/mg protein) 177 ± 15 226 ± 11 1,175 ± 59a
Mn2+-stimulated AC (pmol/min/mg protein) 484 ± 41 526 ± 11 1,814 ± 78a
Values were combined across both cohorts (controls used for CPF administration on GD9–12 and on GD17–20); however,
statistical comparisons of the effects of CPF were made only with the appropriately matched control cohort.
aSigniﬁcant difference between GD21 forebrain and brainstem.statistical comparisons of the effects of CPF
were made only with the appropriately
matched control cohort.
Results
Development of βAR binding and AC in
controls. βARs in both the forebrain and
brainstem were higher than the values in whole
brain in samples collected on GD17, and
regional differences were apparent, with higher
binding in the brainstem (Table 1). Similarly,
AC activities in GD21 samples were much
higher in the brainstem than in the forebrain.
To assess whether the differences in βARs cor-
responded to enhanced AC sensitivity to recep-
tor stimulation, we assessed the response to the
isoproterenol relative to basal activity and to
the maximum Gs-sensitive AC response as
assessed with forskolin (Figure 1A). Across all
regions, isoproterenol caused a small but signif-
icant stimulation over basal activity (ratio > 1,
p < 0.03). However, the response was signiﬁ-
cant only for GD17 whole brain (p < 0.008)
and GD21 brainstem (p < 0.002) and not for
GD21 forebrain. Similarly, although GD17
whole brain and GD21 brainstem showed an
equivalent proportion of isoproterenol
response relative to forskolin, the value was sig-
niﬁcantly lower for GD21 forebrain. Thus, the
absolute concentration of βARs did not pro-
vide the primary determinant of the response
to isoproterenol. The higher AC activity seen
in the brainstem was also accompanied by dif-
ferential effects on the response to the two
direct AC stimulants, forskolin and Mn2+
(Figure 1B). Although forskolin stimulation
was relatively consistent as a proportion to
basal activity, the Mn2+-mediated response in
the brainstem was 50% lower. Calculated as
the forskolin/Mn2+ ratio, values were 0.37 ±
0.01 in whole brain collected on GD17 and
0.43 ± 0.02 in the GD21 forebrain, whereas it
was significantly higher in the GD21 brain-
stem (0.65 ± 0.02, p < 0.0001 vs. brainstem).
Systemic toxicity of CPF. As reported pre-
viously (Garcia et al. 2002; Qiao et al. 2002),
the threshold for CPF-induced impairment of
maternal growth was 5 mg/kg with treatment
on either GD9–12 or GD17–20, but fetal
brain growth was unaffected even at the high-
est doses (data not shown). Neither the early
nor the late treatment paradigm affected the
number of fetuses or fetal viability. Fetal brain
cholinesterase showed signiﬁcant inhibition at
≥ 5 mg/kg (Qiao et al. 2002).
CPF exposure on GD17–20. Before exam-
ining the effects of CPF on each variable and
each brain region, a global ANOVA was per-
formed across both regions and all measure-
ments so as to avoid type 1 statistical errors
that would otherwise result from multiple tests
on the same data set. The overall test indicated
a significant main effect of CPF (p < 0.003)
and interactions of treatment with region and
type of measurement: p < 0.007 for treatment
× region, p < 0.0001 for treatment × measure,
and p < 0.03 for treatment × region × measure.
Accordingly, the results were separated into
the two regions for further analysis of treat-
ment effects on each measure.
In the forebrain, animals treated with CPF
from GD17 through GD20 displayed robust
(> 40%) βAR decreases at 2 mg/kg, a dose
below the threshold for systemic toxicity and at
which cholinesterase inhibition is barely
detectable (Qiao et al. 2002) (Figure 2A).
However, the response displayed distinct
hormesis (i.e., was nonmonotonic), disappear-
ing as the dose was raised above the toxicity
threshold. Across all AC measures, CPF
elicited a net increase in activity (main effect),
but the magnitude of enhancement differed
among the various stimulants (treatment ×
measure interaction). Basal and isoproterenol-
stimulated AC activity showed no signiﬁcant
changes overall, whereas the responses to
forskolin and Mn2+ showed major increases
only at doses of > 10 mg/kg. When activities
were determined relative to basal AC, there
were some speciﬁc differences from the pattern
seen for absolute AC activity, but the overall
pattern was similar (Figure 2B). Isoproterenol-
mediated responses were signiﬁcantly elevated
by small amounts, and the enhanced responses
to the two direct AC stimulants were fully evi-
dent. Nevertheless, all these effects involved
CPF doses of ≥ 5 mg/kg. There were no
changes in the forskolin/Mn2+ response ratio
that would have accompanied a shift in the AC
isoform (Zeiders et al. 1999b).
In the brainstem, CPF elicited alterations
in βAR binding and AC activities that were in
the same direction as those seen in the fore-
brain, but the dose–effect relationships were
distinctly different (Figure 3A). The decrement
of βAR binding was evident even at the lowest
dose of CPF, which lies below the threshold
for detectable cholinesterase inhibition (Qiao
et al. 2002); again, the response was hormetic
and disappeared once the dose was raised
above the toxicity threshold. Overall stimula-
tion of AC displayed differential effects
depending on the test stimulant (treatment ×
measure interaction). In this case, unlike in the
forebrain, every single measure of AC showed
signiﬁcant augmentation after CPF treatment.
Responses displayed hormesis for basal and
isoproterenol-stimulated AC. For forskolin and
Mn2+, the enhancement was evident at
2 mg/kg, a lower dose than that required for
effects in the forebrain. Because of the differen-
tial effects on disparate measures of AC activ-
ity, we reexamined the responses as relative
ratios (Figure 3B). Although the absolute
response to isoproterenol was augmented, the
effect was actually no greater than the change
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Figure 1. Development of AC responses to isopro-
terenol (A) and to forskolin and Mn2+ (B) relative to
basal AC activity in controls. Iso, isoproterenol.
Data are presented as mean ± SE of six determina-
tions on samples collected on GD17 and 17–18
determinations for those collected on GD21.
ANOVA results for each measure appear within the
figure, and lines and asterisks denote individual
groups that differ signiﬁcantly from each other.
Figure 2. Effects of CPF exposure on GD17–20 on
forebrain βAR binding and AC activity measured on
GD21. Abbreviations: Iso, isoproterenol; Rx, treat-
ment. (A) Effects on absolute activities. (B) Activity
ratios. Data represent mean ± SE obtained from
five to seven animals for each group. ANOVA
results for each measure appear within the ﬁgure,
and asterisks denote individual groups that differ
signiﬁcantly from the corresponding control.
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basal activity ratio was unaffected. In contrast,
the isoproterenol/forskolin response ratio
showed signiﬁcant decrements, indicating that
βAR-mediated responses were suboptimal after
CPF treatment. Forskolin- and Mn2+-stimu-
lated AC activities remained signiﬁcantly ele-
vated after correction for basal AC, but the
effects were not as robust until the dose was
raised above 5 mg/kg. As was true in the fore-
brain, the brainstem also showed no change in
the forskolin/Mn2+ activity ratio.
CPF exposure on GD9–12. For examina-
tion of the effects of CPF during neurulation,
the dose range was more restricted, encompass-
ing exposures below and up to the threshold
for systemic toxicity (Qiao et al. 2002). Across
all measures and the three different tissues
(GD17 whole brain, GD21 forebrain, GD21
brainstem), global ANOVA indicated a signiﬁ-
cant interaction of treatment × measure
(p < 0.03), and accordingly, we then assessed
each measurement separately. This lower-order
test indicated signiﬁcant effects on βAR bind-
ing (p < 0.04 for main treatment effect,
p < 0.09 for treatment × tissue) but not for AC
activities. The absence of significant overall
effects on AC should be interpreted with cau-
tion, however, because it mixes together the
effects in whole brain on GD17 with those of
the two separate regions on GD21. Restricting
the analysis to the latter measurements, we
detected a signiﬁcant overall decrement in AC
at the highest CPF dose (p < 0.0006 for main
effect). In any case, the direction of change
with this regimen was opposite that obtained
with treatment on GD17–20 and was statisti-
cally distinguishable from those effects
(p < 0.06 for treatment × region × regimen).
Examining each age and tissue indepen-
dently, the effects of CPF on GD17 were rela-
tively minor and did not achieve statistical
significance for any of the measurements
(Figure 4A). By GD21, there was signiﬁcant
augmentation of βAR binding in the forebrain
Figure 4B), with effects fully evident at
2 mg/kg, a dose below the threshold for sys-
temic toxicity (Qiao et al. 2002). No such
effect was seen in the brainstem (Figure 4C),
and the regional difference was statistically
robust (p < 0.02 for treatment × region). As
noted above, AC activities were significantly
decreased overall across the two regions on
GD21 at the highest dose, although the
absence of a treatment × measure interaction
did not permit us to examine the signiﬁcance
of each measurement separately.
Discussion
Results of the present study indicate that gesta-
tional exposure to CPF evokes immediate
alterations in AC-mediated cell signaling in the
developing brain, with a distinct regional hier-
archy and critical window of vulnerability. It is
highly unlikely that CPF interacts directly with
the signaling proteins of this intracellular trans-
duction cascade or that it simply causes global
alterations in the expression or function of the
proteins, because in those situations, effects
would have been temporally and spatially uni-
form. Because cAMP is a pivotal control point
for the trophic control of cell replication and
differentiation by neurotransmitters and hor-
mones (Bhat et al. 1983; Claycomb 1976;
Guidotti 1972; Hultgårdh-Nilsson et al. 1994;
Van Wijk et al. 1973), the complex series of
changes in AC signaling elicited by develop-
mental exposure to CPF provides a mechanism
for deleterious outcomes.
By far the greatest period of sensitivity was
late gestation after CPF exposure on GD17–20.
We observed signiﬁcant βAR deﬁcits at doses
below the threshold for maternal or fetal sys-
temic toxicity and, indeed, below the level at
which signiﬁcant cholinesterase inhibition can
be detected in the fetal brain (Qiao et al. 2002).
Nevertheless, the AC response mediated by
βARs, isoproterenol-stimulated AC activity,
was unaffected or even increased, indicating
that receptor binding is not the primary deter-
minant of the receptor-mediated signaling
response. These results reinforce the idea that
the expression and function of signaling pro-
teins downstream from the receptor provide the
primary determinants of the net cellular
response to receptor activation (Gao et al.
1998, 1999; Navarro et al. 1991a, 1991b;
Slotkin et al. 2001, 2003). Accordingly, we
evaluated AC responses mediated by direct
stimulants, which test the inherent responsive-
ness of AC itself. CPF exposure on GD17–20
elicited marked increases in AC responses to
forskolin or Mn2+ but with a distinct regional
hierarchy: the brainstem was far more sensitive
than the forebrain. Indeed, in the brainstem,
AC induction was evident with doses as low as
2 mg/kg using either AC stimulant. Because
forskolin and Mn2+ operate through different
epitopes of the AC molecule (Limbird et al.
1979; Seamon and Daly 1986; Zeiders et al.
1999b), the parallel effect of CPF on the
responses to the two agents, unaccompanied
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Figure 3. Effects of CPF exposure on GD17–20 on
brainstem βAR binding and AC activity measured on
GD21. Abbreviations: Iso, isoproterenol; Rx, treat-
ment. (A) Effects on absolute activities. (B) Activity
ratios. Data represent mean ± SE obtained from ﬁve
to seven animals for each group. ANOVA results for
each measure appear within the ﬁgure, and aster-
isks denote individual groups that differ signiﬁcantly
from the corresponding control.
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Figure 4. Effects of CPF exposure on GD9–12 assessed in whole brain on GD17 (A) and in forebrain (B) and brainstem (C) on GD21. Data represent mean ± SE of
ﬁve or six determinations for each group at each age. 
*Individual groups differ signiﬁcantly from the corresponding control (p < 0.04; ANOVA).by a shift in their relative activity (i.e., no
change in the forskolin/Mn2+ response ratio),
implies that CPF treatment increases (induces)
the concentration of AC molecules.
A closer examination of the effects on AC
in the brainstem indicates that the enzyme
induction caused by CPF exposure actually
masks deficits in βAR-mediated responses. 
If there were no changes in the receptor-
mediated component, then the isoproterenol
response would simply mimic the effect seen
on total AC activity. Instead, the proportion
of AC capable of responding to isoproterenol
declined in the CPF group, evidenced by a
drop in the isoproterenol/forskolin response
ratio. Unlike the effects on AC itself, however,
this deficit in the relative βAR response was
detectable only at doses above the threshold
for cholinesterase inhibition.
In contrast to the prominent effects of the
GD17–20 CPF regimen on AC signaling,
similar treatment on GD9–12 elicited little or
no effect; if anything, AC activities tended to
be reduced slightly, rather than increased.
Accordingly, the window of vulnerability for
CPF’s effects on AC signaling appears to be
concentrated in late gestation. Although our
studies do not address the speciﬁc reasons for
the higher liability of late gestational expo-
sure, there are certainly major developmental
differences in the two stages. Within the brain
itself, the basic processes of neurogenesis, glio-
genesis, axonogenesis, cell migration, and
architectural organization are completely dis-
tinct in mid- versus late gestation (Rodier
1988). Further, the later period corresponds
to the onset of sexual differentiation of the
brain. Although CPF is only weakly estro-
genic (Andersen et al. 2002; Vinggaard et al.
2000), effects on neural development are
likely to influence the ontogeny of sexual
dimorphism, endocrine responses, or even
hormonal levels, and CPF intoxication in
adults is known to have secondary endocrine
effects (Guven et al. 1999). In the present
study, we did not examine male and female
fetuses separately. However, in previous work
we found that CPF treatment on GD17–20
produces sex-dependent neurobehavioral dif-
ferences that emerge in adolescence and
adulthood (Levin et al. 2002). If sexual differ-
entiation is a component of CPF’s targeted
effects on brain development, then we would
predict that the effects of earlier exposure on
GD9–12 might not show sex dependence;
these studies are currently under way.
Regardless of the mechanisms underlying
the critical period for effects of CPF on AC, it
is important to note that CPF exerts other
types of developmental neurotoxicant effects in
the earlier phases of development. These
include abnormal patterns of cell replication
and cell death during CPF exposure at the
neural tube stage (Roy et al. 1998), as well as
lasting neurobehavioral effects of such exposure
(Icenogle et al. In Press). Our results indicate
that those effects are not mediated through ini-
tial alterations in the AC cascade, but rather
through other mechanisms. Similarly, the win-
dow for targeted effects on AC components
shows postnatal closure. CPF treatment of
neonatal rats does not augment brainstem or
forebrain AC activity as was seen here for the
late gestational treatment regimen (Song et al.
1997). Instead, the postnatal exposures cause
delayed-onset deterioration of AC signaling
that likely represents a consequence of other
mechanisms contributing to altered cell devel-
opment (Campbell et al. 1997; Dam et al.
1998, 1999a). Findings in the cerebellum, a
region that develops much later than the brain-
stem or forebrain (Rodier 1988), reinforce the
concept of a critical period of cell maturation
in which AC is vulnerable to CPF; postnatal
CPF exposure elicits the same type of immedi-
ate increase in cerebellar AC activity as seen
here for the earlier-developing regions with
gestational CPF treatment (Song et al. 1997).
Finally, it is interesting to note that sev-
eral effects of CPF displayed distinct hormesis
(i.e., the effects were nonmonotonic), with
alterations apparent at low doses but disap-
pearing once the dose was raised above the
threshold for cholinesterase inhibition and
systemic toxicity. A similar phenomenon has
been noted for effects on biomarkers of
synaptic development (Qiao et al. 2002,
2003) and for behavioral consequences of ges-
tational or neonatal CPF treatment (Levin
et al. 2001, 2002; Icenogle et al. In Press).
Cholinergic input provides a positive trophic
effect on brain development at the levels of
cell maturation and regional architecture
(Hohmann and Berger-Sweeney 1998;
Lauder and Schambra 1999), and it is thus
possible that raising the dose of CPF above
the threshold for cholinesterase inhibition can
partially offset deleterious effects mediated by
noncholinergic mechanisms. Consequently,
the dose–effect curve for the developmental
neurotoxicity of CPF can be expected to dis-
play multiple phases, not a monotonic rela-
tionship. This also points out an inherent
difﬁculty in ascribing any effects of CPF in an
in vivo treatment model to a definitive
“cholinergic” or “noncholinergic” mecha-
nism. Effects on signaling pathways, such as
the AC pathway, no doubt have an inﬂuence
on responses mediated by cholinergic signals,
which operate in part through cAMP. In turn,
cholinergic effects influence AC and cAMP
formation. Resolution of these issues thus ulti-
mately requires simpliﬁed systems such as cell
cultures or lower organisms (Buznikov et al.
2001; Schuh et al. 2002; Song et al. 1998).
The present study thus reinforces the idea
that CPF elicits developmental neurotoxicity
through mechanisms independent of, and at
doses below the threshold for, cholinesterase
inhibition. The AC signaling cascade repre-
sents a major control point for brain cell repli-
cation and differentiation, and CPF targets
this intracellular pathway with discrete tempo-
ral and regional selectivity. In addition to
immediate changes in AC signaling, CPF also
has the potential to evoke delayed-onset alter-
ations (Song et al. 1997) that may influence
later maturational events such as axonogenesis,
synaptogenesis, and synaptic function (Barone
et al. 2000; Das and Barone 1999; Pope 1999;
Schuh et al. 2002; Slotkin 1999. In press).
Accordingly, future studies will need to
address the issue of the long-term effects of
gestational CPF exposure on the AC pathway.
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